141 related articles for article (PubMed ID: 24256157)
1. Regaining control: the patient experience of supervised compared with unsupervised consumption in opiate substitution treatment.
Notley C; Holland R; Maskrey V; Nagar J; Kouimtsidis C
Drug Alcohol Rev; 2014 Jan; 33(1):64-70. PubMed ID: 24256157
[TBL] [Abstract][Full Text] [Related]
2. Treatment retention, drug use and social functioning outcomes in those receiving 3 months versus 1 month of supervised opioid maintenance treatment. Results from the Super C randomized controlled trial.
Holland R; Maskrey V; Swift L; Notley C; Robinson A; Nagar J; Gale T; Kouimtsidis C
Addiction; 2014 Apr; 109(4):596-607. PubMed ID: 24304349
[TBL] [Abstract][Full Text] [Related]
3. Supervised dosing with a long-acting opioid medication in the management of opioid dependence.
Saulle R; Vecchi S; Gowing L
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011983. PubMed ID: 28447766
[TBL] [Abstract][Full Text] [Related]
4. Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence.
Godersky ME; Saxon AJ; Merrill JO; Samet JH; Simoni JM; Tsui JI
Addict Sci Clin Pract; 2019 Mar; 14(1):11. PubMed ID: 30867068
[TBL] [Abstract][Full Text] [Related]
5. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
6. A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: do stable patients receive more unsupervised doses?
Larance B; Carragher N; Mattick RP; Lintzeris N; Ali R; Degenhardt L
Drug Alcohol Depend; 2014 Sep; 142():46-55. PubMed ID: 25015687
[TBL] [Abstract][Full Text] [Related]
7. Exploring the Concepts of Abstinence and Recovery Through the Experiences of Long-Term Opiate Substitution Clients.
Notley C; Blyth A; Maskrey V; Pinto H; Holland R
Subst Abus; 2015; 36(2):232-9. PubMed ID: 25127184
[TBL] [Abstract][Full Text] [Related]
8. Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.
Yarborough BJ; Stumbo SP; McCarty D; Mertens J; Weisner C; Green CA
Drug Alcohol Depend; 2016 Mar; 160():112-8. PubMed ID: 26796596
[TBL] [Abstract][Full Text] [Related]
9. Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder.
Bishop B; Gilmour J; Deering D
Int J Ment Health Nurs; 2019 Feb; 28(1):226-236. PubMed ID: 30019812
[TBL] [Abstract][Full Text] [Related]
10. Commentary on Holland et al. (2014): Opioid maintenance treatment--how much supervision is helpful?
Koller G
Addiction; 2014 Apr; 109(4):608-9. PubMed ID: 24605959
[No Abstract] [Full Text] [Related]
11. Characteristics and quality of life of opioid-dependent pregnant women in Austria.
Metz VE; Comer SD; Wuerzl J; Pribasnig A; Fischer G
Arch Womens Ment Health; 2014 Dec; 17(6):529-39. PubMed ID: 25023716
[TBL] [Abstract][Full Text] [Related]
12. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder.
Fox AD; Maradiaga J; Weiss L; Sanchez J; Starrels JL; Cunningham CO
Addict Sci Clin Pract; 2015 Jan; 10(1):2. PubMed ID: 25592182
[TBL] [Abstract][Full Text] [Related]
13. A mixed-methods analysis of patient safety incidents involving opioid substitution treatment with methadone or buprenorphine in community-based care in England and Wales.
Gibson R; MacLeod N; Donaldson LJ; Williams H; Hibbert P; Parry G; Bhatt J; Sheikh A; Carson-Stevens A
Addiction; 2020 Nov; 115(11):2066-2076. PubMed ID: 32149443
[TBL] [Abstract][Full Text] [Related]
14. A pilot randomised controlled trial of brief versus twice weekly versus standard supervised consumption in patients on opiate maintenance treatment.
Holland R; Matheson C; Anthony G; Roberts K; Priyardarshi S; Macrae A; Whitelaw E; Appavoo S; Bond C
Drug Alcohol Rev; 2012 Jun; 31(4):483-91. PubMed ID: 22150819
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation: a comparison of methadone versus buprenorphine for opiate substitution treatment.
Maas J; Barton G; Maskrey V; Pinto H; Holland R
Drug Alcohol Depend; 2013 Dec; 133(2):494-501. PubMed ID: 23962419
[TBL] [Abstract][Full Text] [Related]
16. Consumer attitudes about opioid addiction treatment: a focus group study in New York City.
Sohler NL; Weiss L; Egan JE; López CM; Favaro J; Cordero R; Cunningham CO
J Opioid Manag; 2013; 9(2):111-9. PubMed ID: 23709320
[TBL] [Abstract][Full Text] [Related]
17. Comparison of methadone and buprenorphine for opiate detoxification (LEEDS trial): a randomised controlled trial.
Wright NM; Sheard L; Adams CE; Rushforth BJ; Harrison W; Bound N; Hart R; Tompkins CN
Br J Gen Pract; 2011 Dec; 61(593):e772-80. PubMed ID: 22137413
[TBL] [Abstract][Full Text] [Related]
18. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
Curcio F; Franco T; Topa M; Baldassarre C;
Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
[TBL] [Abstract][Full Text] [Related]
19. Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication.
Bruce RD; Eiserman J; Acosta A; Gote C; Lim JK; Altice FL
Am J Drug Alcohol Abuse; 2012 May; 38(3):206-12. PubMed ID: 22242700
[TBL] [Abstract][Full Text] [Related]
20. Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients.
Larance B; Degenhardt L; O'Brien S; Lintzeris N; Winstock A; Mattick RP; Bell J; Ali R
Drug Alcohol Rev; 2011 Nov; 30(6):613-20. PubMed ID: 21355939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
